Filaments line up as MS biomarker

Neurofilament assays appear on track to become the biomarker of choice for a wide range of neurodegeneration studies, given their tight correlation with axon damage and detectability in blood.

If prospective trials can reinforce the positive data from retrospective clinical studies, the biomarker could see wide uptake in multiple sclerosis and beyond...